Highlights

  • IHE seeks exposure to US pharmaceutical equities including drug and Vaccine producers.
  • The fund reports NAV of USD 106.81 as of 2 November 2026.
  • IHE lists an expense ratio of 0.37% and distributes quarterly.

iShares U.S. Pharmaceuticals ETF (NYSE Arca:IHE) seeks to track US pharmaceutical equities including drug and vaccine producers. Its NAV stood at USD 106.81 as of 2 November 2026. Net Assets totalled USD 1,612,898,805 as of 2 November 2026.

Drug Manufacturers Within a Pharmaceutical Index

IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index. The benchmark includes companies Manufacturing prescription medicines, over-the-counter products and vaccines. It can include businesses of different sizes within the pharmaceuticals sector.

The fund uses representative sampling, selecting investments intended to resemble the benchmark’s overall characteristics. It may therefore hold a different collection of securities from the index while seeking a similar Investment profile.

Portfolio Composition and Exposure

IHE reported 53 holdings as of 30 October 2026. Its allocation by Market Value included Pharmaceuticals at 99.94% and Cash and/or Derivatives at 0.06% as of 30 October 2026.

The fact sheet dated 30 September 2026 identified holdings including Eli Lilly at 23.51%, Johnson & Johnson at 22.64% and Pfizer at 4.69%. These position weights refer to that reporting date and can change as the portfolio and market values evolve.

The same fact sheet reported a P/E ratio of 26.25x and a P/B ratio of 5.18x. These valuation measures complement the holdings information with Earnings and book-value characteristics associated with the Equity portfolio.

Fees and Distribution Policy

The published expense ratio is 0.37%. Distributions are scheduled quarterly.

The 30-day SEC Yield was 1.19% as of 30 September 2026. This standardised income measure reflects the fund’s recent income after expenses; it is separate from changes in the market value of its shares.

The prospectus notes that brokerage commissions and other intermediary charges may apply separately. Fund shares trade at market prices, which can differ from NAV, so the stated NAV does not establish the price of every exchange transaction.

Key Insights

Product approvals, regulation, Patent protection and competition can affect pharmaceutical businesses. The industry mandate links the fund to those conditions while retaining exposure to individual product and company developments.